Who Buys Taila from India — 381 Importers Behind a $7.6M Market

The importation of Taila from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like SWASTHYAM AYURVEDA HANDEL (Germany) and BENEVIT S.R.O. (Slovak Republic) function as intermediaries, procuring Taila in bulk to supply to retailers, healthcare providers, and other end-users. Their order patterns are characterized by large, regular shipments to maintain a steady supply chain.

• Hospital Groups: Organizations such as KEM EVANG, KLINKIKEN ESSEN-MITTE-GG (Germany) import Taila directly for therapeutic use within their facilities. Their procurement is typically based on patient demand and treatment protocols, leading to consistent, scheduled orders.

• Retail Chains: Companies like KOTTAKKAL AYURVEDIC MEDICALS LLC (United Arab Emirates) import Taila to stock their retail outlets, catering to consumer demand for Ayurvedic products. Their purchasing behavior is influenced by market trends and consumer preferences, resulting in variable order sizes and frequencies.

• Re-exporters: Entities such as HEALTH CARE HERBAL TRADING PPC LLC (United Arab Emirates) and SABHA GENERAL TRADING CO LLC (United Arab Emirates) import Taila with the intent to re-export to other markets. Their buying patterns are opportunistic, based on global demand fluctuations and trade opportunities.

• Contract Manufacturers: Companies like HATAY PHARMACEUTICAL JOINT STOCK CO (Vietnam) may import Taila as a raw material for the production of finished pharmaceutical products. Their procurement is aligned with production schedules and client orders, leading to periodic, bulk purchases.

Germany

1. Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).

2. Import Registration Process: Importers must submit a marketing authorization application to BfArM, including comprehensive documentation on product quality, safety, and efficacy.

3. Estimated Timeline: The registration process typically takes 7 to 12 months, depending on the completeness of the application and any additional information requests.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049011 are generally subject to a 0% import duty within the European Union.

Saudi Arabia

1. Regulatory Authority: Saudi Food and Drug Authority (SFDA).

2. Import Registration Process: Importers must obtain product registration from the SFDA, which involves submitting detailed product information, including manufacturing practices and clinical data.

3. Estimated Timeline: The registration process can take approximately 6 to 9 months, subject to the SFDA's review and approval procedures.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049011 are typically exempt from import duties in Saudi Arabia.

United Arab Emirates

1. Regulatory Authority: Ministry of Health and Prevention (MOHAP).

2. Import Registration Process: Importers are required to register pharmaceutical products with MOHAP, providing detailed dossiers on product specifications, safety, and efficacy.

3. Estimated Timeline: The registration process usually takes between 6 to 12 months, depending on the complexity of the product and the review process.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049011 are generally exempt from import duties in the UAE.

Slovak Republic

1. Regulatory Authority: State Institute for Drug Control (ŠÚKL).

2. Import Registration Process: Importers must apply for marketing authorization from ŠÚKL, submitting comprehensive documentation on product quality, safety, and efficacy.

3. Estimated Timeline: The registration process typically takes 7 to 12 months, depending on the completeness of the application and any additional information requests.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049011 are generally subject to a 0% import duty within the European Union.

Russia

1. Regulatory Authority: Ministry of Health of the Russian Federation.

2. Import Registration Process: Importers must obtain a registration certificate from the Ministry of Health, which involves submitting detailed product information, including clinical trial data and manufacturing practices.

3. Estimated Timeline: The registration process can take approximately 12 to 18 months, subject to the Ministry's review and approval procedures.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049011 are typically subject to an import duty of 5% in Russia.

The demand for Taila in importing countries is influenced by several factors:

• Disease Prevalence: Taila is traditionally used in Ayurvedic medicine for various therapeutic purposes. The prevalence of conditions treatable by Taila, such as musculoskeletal disorders and certain skin conditions, drives its demand in countries with a growing interest in alternative and complementary medicine.

• Government Healthcare Programs: Countries expanding their healthcare programs to include traditional and alternative medicines contribute to the increased demand for products like Taila. For instance, the inclusion of Ayurvedic treatments in national health policies can lead to higher procurement rates.

• Universal Health Coverage Expansion: As nations strive to achieve universal health coverage, there is a growing emphasis on integrating traditional medicines into mainstream healthcare systems, thereby boosting the demand for products like Taila.

• WHO Essential Medicines List Procurement: While Taila is not listed on the WHO Essential Medicines List, the organization's support for traditional medicine practices encourages countries to procure such products to meet public health needs.

• Tender-Based Purchasing: Public sector procurement through tenders, especially in countries with established tender boards, facilitates the bulk purchasing of medicines, including traditional products like Taila. This system ensures a steady supply to meet the healthcare demands of the population.

With 381 buyers across 82 countries, the market for Taila demonstrates a broad and diverse demand base, indicating significant opportunities for expansion and increased market penetration.

The importation of Taila from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like SWASTHYAM AYURVEDA HANDEL (Germany) and BENEVIT S.R.O. (Slovak Republic) function as intermediaries, procuring Taila in bulk to supply to retailers, healthcare providers, and other end-users. Their order patterns are characterized by large, regular shipments to maintain a steady supply chain.

• Hospital Groups: Organizations such as KEM EVANG, KLINKIKEN ESSEN-MITTE-GG (Germany) import Taila directly for therapeutic use within their facilities. Their procurement is typically based on patient demand and treatment protocols, leading to consistent, scheduled orders.

• Retail Chains: Companies like KOTTAKKAL AYURVEDIC MEDICALS LLC (United Arab Emirates) import Taila to stock their retail outlets, catering to consumer demand for Ayurvedic products. Their purchasing behavior is influenced by market trends and consumer preferences, resulting in variable order sizes and frequencies.

• Re-exporters: Entities such as HEALTH CARE HERBAL TRADING PPC LLC (United Arab Emirates) and SABHA GENERAL TRADING CO LLC (United Arab Emirates) import Taila with the intent to re-export to other markets. Their buying patterns are opportunistic, based on global demand fluctuations and trade opportunities.

• Contract Manufacturers: Companies like HATAY PHARMACEUTICAL JOINT STOCK CO (Vietnam) may import Taila as a raw material for the production of finished pharmaceutical products. Their procurement is aligned with production schedules and client orders, leading to periodic, bulk purchases.

Germany

1. Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).

2. Import Registration Process: Importers must submit a marketing authorization application to BfArM, including comprehensive documentation on product quality, safety, and efficacy.

3. Estimated Timeline: The registration process typically takes 7 to 12 months, depending on the completeness of the application and any additional information requests.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049011 are generally subject to a 0% import duty within the European Union.

Saudi Arabia

1. Regulatory Authority: Saudi Food and Drug Authority (SFDA).

2. Import Registration Process: Importers must obtain product registration from the SFDA, which involves submitting detailed product information, including manufacturing practices and clinical data.

3. Estimated Timeline: The registration process can take approximately 6 to 9 months, subject to the SFDA's review and approval procedures.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049011 are typically exempt from import duties in Saudi Arabia.

United Arab Emirates

1. Regulatory Authority: Ministry of Health and Prevention (MOHAP).

2. Import Registration Process: Importers are required to register pharmaceutical products with MOHAP, providing detailed dossiers on product specifications, safety, and efficacy.

3. Estimated Timeline: The registration process usually takes between 6 to 12 months, depending on the complexity of the product and the review process.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049011 are generally exempt from import duties in the UAE.

Slovak Republic

1. Regulatory Authority: State Institute for Drug Control (ŠÚKL).

2. Import Registration Process: Importers must apply for marketing authorization from ŠÚKL, submitting comprehensive documentation on product quality, safety, and efficacy.

3. Estimated Timeline: The registration process typically takes 7 to 12 months, depending on the completeness of the application and any additional information requests.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049011 are generally subject to a 0% import duty within the European Union.

Russia

1. Regulatory Authority: Ministry of Health of the Russian Federation.

2. Import Registration Process: Importers must obtain a registration certificate from the Ministry of Health, which involves submitting detailed product information, including clinical trial data and manufacturing practices.

3. Estimated Timeline: The registration process can take approximately 12 to 18 months, subject to the Ministry's review and approval procedures.

4. Import Tariff/Duty: Pharmaceutical products under HS Code 30049011 are typically subject to an import duty of 5% in Russia.

The demand for Taila in importing countries is influenced by several factors:

• Disease Prevalence: Taila is traditionally used in Ayurvedic medicine for various therapeutic purposes. The prevalence of conditions treatable by Taila, such as musculoskeletal disorders and certain skin conditions, drives its demand in countries with a growing interest in alternative and complementary medicine.

• Government Healthcare Programs: Countries expanding their healthcare programs to include traditional and alternative medicines contribute to the increased demand for products like Taila. For instance, the inclusion of Ayurvedic treatments in national health policies can lead to higher procurement rates.

• Universal Health Coverage Expansion: As nations strive to achieve universal health coverage, there is a growing emphasis on integrating traditional medicines into mainstream healthcare systems, thereby boosting the demand for products like Taila.

• WHO Essential Medicines List Procurement: While Taila is not listed on the WHO Essential Medicines List, the organization's support for traditional medicine practices encourages countries to procure such products to meet public health needs.

• Tender-Based Purchasing: Public sector procurement through tenders, especially in countries with established tender boards, facilitates the bulk purchasing of medicines, including traditional products like Taila. This system ensures a steady supply to meet the healthcare demands of the population.

With 381 buyers across 82 countries, the market for Taila demonstrates a broad and diverse demand base, indicating significant opportunities for expansion and increased market penetration.